suma/protease

FIELD OF THE INVENTION The present invention relates to subtilisin protease conjugates and compositions comprising the conjugates which have decreased immunogenicity relative to their corresponding parent proteases. BACKGROUND OF THE INVENTION Enzymes make up the largest class of naturally occurring

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to novel addition compounds of dipeptide derivative and amino acid derivative and a process for producing the addition compound. More particularly it relates to novel addition compounds of the dipeptides composed of

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to novel addition compounds of dipeptide derivative and amino acid derivative and a process for producing the addition compound. More particularly, it relates to novel addition compounds of the dipeptides composed of

FIELD OF THE INVENTION The present invention relates to chemically modified subtilisin proteases which are useful in compositions such as, for example, personal care compositions, laundry compositions, hard surface cleansing compositions, and light duty cleaning compositions. BACKGROUND OF THE

The invention relates to a method for the determination of the activity of serine proteases or serine protease inhibitors in plasma or other biological fluids. The body has two systems, which are in equilibrium, to protect itself both from blood loss and from thrombosis: the coagulation system and

FIELD OF THE INVENTION The present invention relates to chemically modified subtilisin proteases which are useful in compositions such as, for example, personal care compositions, laundry compositions, hard surface cleansing compositions, and light duty cleaning compositions. BACKGROUND OF THE

This application is a U.S. national stage of International Application No. PCT/JP2009/063547 filed Jul. 30, 2009. TECHNICAL FIELD The present invention relates to a novel protease and use thereof. In particular, the present invention relates to a novel protease having a high activity under high

The invention relates to mutants of factor VII-activating protease (FSAP) and to reduced blood plasma levels of FSAP as indicators of an increased risk for the development and progression of atherothrombosis (or arterial thrombosis) and of the pathophysiological sequelae resulting

The invention relates to mutants of factor VII-activating protease (FSAP) and to reduced blood plasma levels of FSAP as indicators of an increased risk for the development and progression of atherothrombosis (or arterial thrombosis) and of the pathophysiological sequelae resulting

TECHNICAL FIELD The present invention relates to a process for the preparation of (2S,3S,5S)-5-(N-(N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)-amino)ca rbonyl)valinyl)amino)-2-(N-((5-thiazolyl)methoxycarbonyl)-amino)-1,6-diphen yl-3-hydroxyhexane. BACKGROUND OF THE INVENTION It has recently

FIELD OF THE INVENTION The present invention relates to an alkaline protease VapK suitable for a laundry detergent, produced by Vibrio metschnikovii KS1, and to the gene vapk coding for said protease. BRIEF DESCRIPTION OF THE DRAWINGS FIG. 1 shows the restriction map of the recombinant plasmid pSB1

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage of International Application No. PCT/SE2003/001931, filed Dec. 11, 2003, which claims the benefit of Swedish Patent Application Serial No. 0203712-5, filed Dec. 13, 2002. The contents of both applications are hereby

The present invention relates to compounds and compositions for treating diseases associated with cysteine protease activity. The compounds are reversible inhibitors of cysteine proteases S, K, F, L and B. Of particular interest are diseases associated with Cathepsin S. In addition this invention

FIELD OF THE INVENTION The present invention provides methods for protein engineering and serine protease variants produced therefrom. Specifically, the present invention provides serine protease variants having one or more substitutions as compared to a reference serine protease. In addition, the

FIELD OF INVENTION The present invention relates to a group of proteolytic enzymes or proteases isolated from the genus Carica. In particular, the proteolytic enzymes are cysteine proteases that function as mitogenic stimulators of mammalian cells. The present invention also relates to a process for